Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06846463 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 30, 2025 to May 27, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
Trial Details
NCT Number NCT06846463
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Related terms Dendritic Cell Sarcoma, Interdigitating, Lymphoma, Large B-Cell, Diffuse
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov